GORE CARDIOFORM Septal Occluder
W. L. Gore & Associates, Inc. · Decision date May 8, 2026
What did the FDA decide?
FDA records P050006/S118 as a supplement to PMA P050006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 8, 2026.
FDA approval order statement
to add an additional bake step to the delivery system component manufacturing process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- May 8, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P050006/S118
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- MLV
- Decision code
- OK30
- Decision date
- May 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transcatheter septal occluder.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- MLV
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P050006/S116 · Related supplement
GORE CARDIOFORM Septal Occluder; GORE CARDIOFORM ASD Occluder
P050006/S117 · Related supplement
GORE CARDIOFORM ASD Occluder; GORE CARDIOFORM Septal Occluder
P050006/S118 received
Application receipt date recorded by FDA.
P050006/S118 · FDA decision
30-Day Notice
P050006/S119 · Related supplement
GORE CARDIOFORM Septal Occluder; GORE CARDIOFORM ASD Occluder
Timeline entries are records held by MedtechLedger for P050006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA supplement | Dec 19, 2025 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Feb 20, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Aug 3, 2026 | FDA |
Explore the linked device profile
Other records with product code MLV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | May 28, 2026 | FDA | |
AmplatzerTM Muscular VSD OccluderP040040/S051 | ABBOTT MEDICAL | PMA supplement | May 28, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | May 28, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 23, 2025 | FDA | |
Amplatzer Muscular VSD OccluderP040040/S050 | ABBOTT MEDICAL | PMA supplement | Oct 23, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 32360 N. N. Valley Pkwy., Phonix, AZ, 85085
Sources and methodology
- Original FDA record: P050006/S118
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


